Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 400.01B |
| Revenue (ttm) | 78.54B |
| Net Income (ttm) | 21.41B |
| Shares Out | n/a |
| EPS (ttm) | 8.82 |
| PE Ratio | 18.68 |
| Forward PE | 17.21 |
| Dividend | 4.62 (2.79%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 3,051 |
| Average Volume | 704 |
| Open | 165.90 |
| Previous Close | 165.28 |
| Day's Range | 165.44 - 166.60 |
| 52-Week Range | 129.00 - 168.00 |
| Beta | n/a |
| RSI | 70.38 |
| Earnings Date | Oct 14, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson (JNJ) Reports Promising Results for Amivantamab in Cancer Study
Johnson & Johnson (JNJ) Reports Promising Results for Amivantamab in Cancer Study
Johnson & Johnson (JNJ) Boosts Guidance Amid Strategic Unit Separation
Johnson & Johnson (JNJ) Boosts Guidance Amid Strategic Unit Separation
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-...
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.
Dividend Roundup: Citigroup, Johnson & Johnson, Caterpillar, Procter & Gamble, and more
Johnson & Johnson lawsuit explained: Families sue over baby powder cancer claims
Thousands in the UK are suing Johnson & Johnson, alleging that the company's baby powder products concealed cancer risks
Johnson & Johnson (JNJ) Faces Legal Challenges in UK Over Talc Products
Johnson & Johnson (JNJ) Faces Legal Challenges in UK Over Talc Products
Johnson & Johnson (JNJ) Faces Legal Challenges Over Alleged Asbestos in Baby Powder
Johnson & Johnson (JNJ) Faces Legal Challenges Over Alleged Asbestos in Baby Powder
Johnson & Johnson faces UK lawsuit over talc cancer claim
Thousands of UK claimants have filed legal action against US pharmaceutical and cosmetics giant Johnson & Johnson alleging people diagnosed with cancers were exposed to asbestos in its talcum powder, ...
Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase
Key PointsJameson Private Wealth Management increased its JNJ position by 39,471 shares, with an estimated trade value of $6.76 million based on the quarter’s average price
Johnson & Johnson (JNJ) Myeloma Treatment Shows Promising Trial Results
Johnson & Johnson (JNJ) Myeloma Treatment Shows Promising Trial Results
‘When I was a child, everyone used it’: woman blames Johnson & Johnson talc for her cancer
Sue Rizzello is among thousands in UK suing the firm, which denies selling baby powder containing asbestos Thousands in UK take legal action against Johnson & Johnson over alleged talc cancer link It ...
Johnson & Johnson's Phase 3 Study Shows Promising Results for Multiple Myeloma
Johnson & Johnson's Phase 3 Study Shows Promising Results for Multiple Myeloma
Johnson & Johnson succeeds in late-stage multiple myeloma trial
Johnson & Johnson’s Tecvayli combo meets main goal in late-stage myeloma trial. Read more here.
Guru Fundamental Report for JNJ
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy of ...
Johnson & Johnson (JNJ) Faces Major UK Lawsuit Over Talc Products
Johnson & Johnson (JNJ) Faces Major UK Lawsuit Over Talc Products
Exclusive: Ulta Beauty’s new CFO is a Johnson & Johnson veteran tasked to help lead the company’s next chapter
Christopher DelOrefice will join the company on Dec. 5.
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (...
J&J hit with first U.K. lawsuits over talc-related cancer claims
Johnson & Johnson (JNJ) stock is in focus as the company faces its first UK lawsuit over allegations that its talc products caused cancer. Read more here.
Thousands in UK open case against Johnson & Johnson over alleged talcum powder cancer link
High court claim says company knowingly sold product containing asbestos and ‘concealed’ risk to public Thousands of people are taking legal action against pharmaceutical company Johnson & Johnson, cl...
Thousands sue Johnson & Johnson in UK over baby powder cancer claims
Claims Johnson & Johnson ‘concealed’ the risk to the public for decades
Thousands sue Johnson & Johnson in UK over cancer claims
Johnson & Johnson (J&J) is facing legal action from thousands of people in the UK who are accusing the global healthcare giant of knowingly selling talcum powder contaminated with asbestos.
Thousands in UK sue Johnson & Johnson over talcum powder cancer risks
The claim involves 3,000 people and focuses on internal memos and scientific reports, seen by the BBC.
J&J faces first UK lawsuits alleging its baby powder caused cancer
Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.